Drug Trial Radar · NCT04736173
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
169
Actual
Start
Feb 8, 2021
Primary completion
Sep 17, 2026
Study completion Sep 17, 2026
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Gilead Sciences
- First posted
- Feb 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Conditions
- Non Small Cell Lung Cancer
- Nonsquamous Non Small Cell Lung Cancer
- Squamous Non Small Cell Lung Cancer
- Lung Cancer
Interventions
DomvanalimabDrug
Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
ZimberelimabDrug
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
CarboplatinDrug
Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
PaclitaxelDrug
Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
PemetrexedDrug
Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
PembrolizumabDrug
Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: From randomization until death from any cause (up to 7 years)
Locations
38 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Columbus, Georgia
Research Site
Kingwood, Texas
Research Site
Blacksburg, Virginia
Research Site
Hong Kong, Hong Kong
Research Site
Johor Bahru, Malaysia
Research Site
Kuala Lumpur, Malaysia
Research Site
Kuantan, Malaysia
Research Site
Kuching, Malaysia
Research Site
Pulau Pinang, Malaysia
Research Site
Putrajaya, Malaysia
Research Site
Davao City, Philippines
Research Site
Manila, Philippines
Research Site
George, South Africa
Research Site
Johannesburg, South Africa
Research Site
Pretoria, South Africa
Research Site
Daegu, South Korea
Research Site
Incheon, South Korea
Research Site
Jinju, South Korea
Research Site
Seoul, South Korea
Research Site
Suwon, South Korea
Research Site
Taichung, Taiwan
Research Site
Bangkok, Thailand
Research Site
Changwat Sara Buri, Thailand
Research Site
Chanthaburi, Thailand
Research Site
Chiang Mai, Thailand
Research Site
Khon Kaen, Thailand
Research Site
Lampang, Thailand
Research Site
Nakhon Nayok, Thailand
Research Site
Nakhon Ratchasima, Thailand
Research Site
Phitsanulok, Thailand
Research Site
Songkhla, Thailand
Research Site
Ubon Ratchathani, Thailand
Research Site
Adana, Turkey (Türkiye)
Research Site
Ankara, Turkey (Türkiye)
Research Site
Edirne, Turkey (Türkiye)
Research Site
Istanbul, Turkey (Türkiye)
Research Site
Kocaeli, Turkey (Türkiye)
Research Site
Hanoi, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.